2021
DOI: 10.1007/s13311-021-01101-x
|View full text |Cite
|
Sign up to set email alerts
|

Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology

Abstract: Frontotemporal dementia encompasses a group of clinical syndromes defined pathologically by degeneration of the frontal and temporal lobes. Historically, these syndromes have been challenging to diagnose, with an average of about three years between the time of symptom onset and the initial evaluation and diagnosis. Research in the field of neuroimaging has revealed numerous biomarkers of the various frontotemporal dementia syndromes, which has provided clinicians with a method of narrowing the differential di… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
29
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 39 publications
(31 citation statements)
references
References 263 publications
(427 reference statements)
2
29
0
Order By: Relevance
“…Increasing evidence suggests that disrupted energy metabolism in CNS is involved in the development of ALS/FTD. Reduced glucose metabolism is observed in the motor-sensory cortex of ALS patients and in the frontal lobes, striatum, and thalamus of FTD patients, including in asymptomatic carriers of the ALS/FTD-linked C9orf72 mutation [32][33][34] . Glycogen, the storage form of glucose, is elevated in ALS mice and in patients' spinal cord tissues 35,36 .…”
Section: Introductionmentioning
confidence: 99%
“…Increasing evidence suggests that disrupted energy metabolism in CNS is involved in the development of ALS/FTD. Reduced glucose metabolism is observed in the motor-sensory cortex of ALS patients and in the frontal lobes, striatum, and thalamus of FTD patients, including in asymptomatic carriers of the ALS/FTD-linked C9orf72 mutation [32][33][34] . Glycogen, the storage form of glucose, is elevated in ALS mice and in patients' spinal cord tissues 35,36 .…”
Section: Introductionmentioning
confidence: 99%
“…The use of positron emission tomography (PET) imaging, in particular, with radiotracers that bind to aggregated forms of tau has facilitated the in vivo detection of tau neuropathology in individuals with AD (reviewed in [19,100,101]). However, tau-PET tracers do not bind strongly to most forms of FTLD-tau pathology and may exhibit off-target binding in individuals with FTLD-TDP pathology [100,101]. Alternatively, the use of CSF- and blood-based protein biomarkers holds great promise for AD [19,20,102] and FTD [21,103], although in the case of FTD, we still cannot discriminate between underlying FTLD-tau and -TDP pathology.…”
Section: Discussionmentioning
confidence: 99%
“…Noteworthy, the patterns of neurodegenerations in bvFTD are often heterogeneous, and structural and metabolic abnormalities vary considerably ( 100 ). Distinctive patterns may be dominantly frontal or frontotemporal, with atrophy broadly restricting these regions, despite the possibility of mild parietal findings.…”
Section: Neuroimaging Evidence and Differential Diagnosis Of Ftd And Bdmentioning
confidence: 99%